- Alcon Board of Directors proposes to elect Raquel C. Bono,
M.D. as a new Board member
- Shareholders asked to exercise voting rights exclusively by
sending voting instructions to the independent representative due
to closed format
- Proposed dividend of CHF 0.20 cash per share with expected
record date of May 2 and payout date on May 5
Alcon (SIX/NYSE: ALC), the global leader in eye care, will hold
its Annual General Meeting (AGM) on April 27, 2022.
Due to the continuing tense situation due to the COVID-19
pandemic, and as a precautionary and prudent measure, Alcon’s Board
of Directors decided to hold the AGM in a closed format without the
personal attendance of shareholders as permitted by Swiss ordinance
and for the safety of Alcon’s shareholders and associates. Alcon
asks its shareholders to exercise their rights at the AGM
exclusively by sending in voting instructions to the independent
representative identified in the voting materials.
Alcon’s Board of Directors proposes to the AGM to elect Raquel
C. Bono, M.D. as a new Board member. A board-certified trauma
surgeon and retired Vice Admiral, US Navy Medical Corps, Dr. Bono
was the first female three-star admiral in the medical field in the
history of the US Navy, as well as the first Asian-American woman
promoted to Vice Admiral. Dr. Bono has been Chief Health Officer at
Viking, Inc. since November 2020 and a Principal at RCB Consulting
since October 2019. She brings to the Alcon Board more than 25
years of experience in healthcare leadership roles and an extensive
track record in the healthcare industry and the areas of government
relations and regulatory/public policy.
The invitation to the AGM, including explanatory information on
individual agenda items, has been published in the Swiss Gazette of
Commerce on March 24, 2022 and is available online at
https://investor.alcon.com/news-and-events/events-and-presentations/event-details/2022/2022-Annual-General-Meeting/default.aspx.
Agenda for Alcon’s
2022 AGM
1.
Approval of the operating and
financial review of Alcon Inc., the annual financial statements of
Alcon Inc. and the consolidated financial statements for 2021
2.
Discharge of the members of the
Board of Directors and the members of the Executive Committee
3.
Appropriation of earnings and
declaration of dividend as per the balance sheet of Alcon Inc. of
December 31, 2021
▪ If approved by the
shareholders, a dividend of CHF 0.20 in cash per share will be
payable with the record date expected to be May 2, 2022 and the
payout date in Switzerland expected to be on or around May 5, 2022.
The Swiss withholding tax of 35% will be deducted from the gross
dividend amount.
4.
Votes on the compensation of the
Board of Directors and of the Executive Committee
4.1
Consultative vote on the 2021
Compensation Report
4.2
Binding vote on the maximum
aggregate amount of compensation of the Board of Directors for the
next term of office, i.e., from the 2022 Annual General Meeting to
the 2023 Annual General Meeting
4.3
Binding vote on the maximum
aggregate amount of compensation of the Executive Committee for the
following financial year, i.e., 2023
5.
Re-election and election of the
Chair and the Members of the Board of Directors
5.1
Re-election of F. Michael Ball (as Member
and Chair)
5.2
Re-election of Lynn D. Bleil (as
Member)
5.3
Re-election of Arthur Cummings (as
Member)
5.4
Re-election of David J. Endicott (as
Member)
5.5
Re-election of Thomas Glanzmann (as
Member)
5.6
Re-election of D. Keith Grossman (as
Member)
5.7
Re-election of Scott Maw (as Member)
5.8
Re-election of Karen May (as Member)
5.9
Re-election of Ines P�schel (as
Member)
5.10
Re-election of Dieter Spälti (as
Member)
5.11
Election of Raquel C. Bono (as Member)
6.
Re-election and election of the
members of the Compensation Committee
6.1
Re-election of Thomas Glanzmann
6.2
Re-election of Karen May
6.3
Re-election of Ines P�schel
6.4
Election of Scott Maw
7.
Re-election of the independent
representative
8.
Re-election of the statutory
auditors
Cautionary Note Regarding
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the safe harbor provisions of the United States
Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: “anticipate,”
“intend,” “commitment,” “look forward,” “maintain,” “plan,” “goal,”
“seek,” “target,” “assume,” “believe,” “project,” “estimate,”
“expect,” “strategy,” “future,” “likely,” “may,” “should,” “will”
and similar references to future periods. An example of a
forward-looking statement includes, among others, statements Alcon
makes regarding the payment of a dividend.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties and risks that
are difficult to predict. Some of these factors are discussed in
our filings with the United States Securities and Exchange
Commission, including our Form 20-F. Should one or more of these
uncertainties or risks materialize, or should underlying
assumptions prove incorrect, actual results may vary materially
from those anticipated. Therefore, you should not rely on any of
these forward-looking statements.
Forward-looking statements in this press release speak only as
of the date they are made, and we assume no obligation to update
forward-looking statements as a result of new information, future
events or otherwise.
About Alcon
Alcon helps people see brilliantly. As the global leader in eye
care with a heritage spanning over 75 years, we offer the broadest
portfolio of products to enhance sight and improve people’s lives.
Our Surgical and Vision Care products touch the lives of more than
260 million people in over 140 countries each year living with
conditions like cataracts, glaucoma, retinal diseases and
refractive errors. Our more than 24,000 associates are enhancing
the quality of life through innovative products, partnerships with
Eye Care Professionals and programs that advance access to quality
eye care. Learn more at www.alcon.com.
Connect with us on Facebook LinkedIn
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220323005766/en/
Investor Relations Daniel
Cravens + 41 589 112 110 (Geneva) + 1 817 615 2789 (Fort Worth)
investor.relations@alcon.com
Media Relations Steven Smith
+ 41 589 112 111 (Geneva) + 1 817 551 8057 (Fort Worth)
globalmedia.relations@alcon.com
Alcon (NYSE:ALC)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Alcon (NYSE:ALC)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024